Circulating levels of citrullinated and MMP-degraded vimentin (VICM) in liver fibrosis related pathology
| Autor: | Vassiliadis, E., Oliveira, C. P., Alvares-da-Silva, M. R., Zhang, C., Carrilho, F. J., Stefano, J. T., Rabelo, F., Pereira, L., Kappel, C. R., Henriksen, K., Veidal, S. S., Vainer, B., Duffin, K. L., Christiansen, C., Leeming, D. J., Karsdal, M. |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2012 |
| Zdroj: | Vassiliadis, E, Oliveira, C P, Alvares-da-Silva, M R, Zhang, C, Carrilho, F J, Stefano, J T, Rabelo, F, Pereira, L, Kappel, C R, Henriksen, K, Veidal, S S, Vainer, B, Duffin, K L, Christiansen, C, Leeming, D J & Karsdal, M 2012, ' Circulating levels of citrullinated and MMP-degraded vimentin (VICM) in liver fibrosis related pathology ', American Journal of Translational Research, vol. 4, no. 4, pp. 403-414 . |
| Popis: | Aim: To investigate whether increased levels of vimentin citrullinated peptides identified by MS in articular cartilage can be measured in pathologies other than rheumatoid arthritis and be utilised for diagnostic purposes. Methods: A monoclonal antibody against the sequence RLRSSVPGV-citrulline (VICM) was developed and evaluated in a carbon tetrachloride (CCl4) (n=52 + 28 controls) rat model of liver fibrosis and two clinical cohorts of adult patients with hepatitis C (HCV) (n=92) and non-alcoholic fatty liver disease (NAFLD) (n=62), and compared to healthy controls. Results: In CCl4-treated rats, mean systemic VICM levels increased 31% at week 12 (176 ng/mL, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|